FDA expected to sharply restrict use of two monoclonal antibodies, spurring a halt in federal shipments of the covid-19 treatments - The Washington Post

11:45am PST - January 24th, 2022    business - The Washington Post

The therapies by Regeneron and Eli Lilly are not effective against the omicron variant, officials said.